Pharmacogenomics in psychiatry: From therapeutic drug monitoring to genomic medicine

S. Crettol; J. De Leon; C. Hiemke; C. B. Eap

doi:10.1038/clpt.2013.221

Pharmacogenomics in psychiatry: From therapeutic drug monitoring to genomic medicine

S. Crettol
, J. De Leon
, C. Hiemke
, C. B. Eap

Producción científica: Article › revisión exhaustiva

54 Citas (Scopus)

Resumen

Psychiatry is increasingly combining new pharmacogenomic findings with therapeutic drug monitoring (TDM) to improve the safety and efficacy of pharmacotherapy. However, a distinction should be made between "nice to know" and "need to know" pharmacogenomic data because many results are statistically significant in meta-analyses but are not clinically relevant due to their low effect sizes. Some examples will illustrate this integration.

Idioma original	English
Páginas (desde-hasta)	254-257
Número de páginas	4
Publicación	Clinical Pharmacology and Therapeutics
Volumen	95
N.º	3
DOI	https://doi.org/10.1038/clpt.2013.221
Estado	Published - mar 2014

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Acceder al documento

10.1038/clpt.2013.221

Otros archivos y enlaces

Citar esto

@article{b8dc868e06d54828b81ab16c5f44ebd0,

title = "Pharmacogenomics in psychiatry: From therapeutic drug monitoring to genomic medicine",

abstract = "Psychiatry is increasingly combining new pharmacogenomic findings with therapeutic drug monitoring (TDM) to improve the safety and efficacy of pharmacotherapy. However, a distinction should be made between {"}nice to know{"} and {"}need to know{"} pharmacogenomic data because many results are statistically significant in meta-analyses but are not clinically relevant due to their low effect sizes. Some examples will illustrate this integration.",

author = "S. Crettol and \{De Leon\}, J. and C. Hiemke and Eap, \{C. B.\}",

year = "2014",

month = mar,

doi = "10.1038/clpt.2013.221",

language = "English",

volume = "95",

pages = "254--257",

number = "3",

}

TY - JOUR

T1 - Pharmacogenomics in psychiatry

T2 - From therapeutic drug monitoring to genomic medicine

AU - Crettol, S.

AU - De Leon, J.

AU - Hiemke, C.

AU - Eap, C. B.

PY - 2014/3

Y1 - 2014/3

N2 - Psychiatry is increasingly combining new pharmacogenomic findings with therapeutic drug monitoring (TDM) to improve the safety and efficacy of pharmacotherapy. However, a distinction should be made between "nice to know" and "need to know" pharmacogenomic data because many results are statistically significant in meta-analyses but are not clinically relevant due to their low effect sizes. Some examples will illustrate this integration.

AB - Psychiatry is increasingly combining new pharmacogenomic findings with therapeutic drug monitoring (TDM) to improve the safety and efficacy of pharmacotherapy. However, a distinction should be made between "nice to know" and "need to know" pharmacogenomic data because many results are statistically significant in meta-analyses but are not clinically relevant due to their low effect sizes. Some examples will illustrate this integration.

UR - https://www.scopus.com/pages/publications/84894473210

UR - https://www.scopus.com/pages/publications/84894473210#tab=citedBy

U2 - 10.1038/clpt.2013.221

DO - 10.1038/clpt.2013.221

M3 - Article

C2 - 24196844

AN - SCOPUS:84894473210

SN - 0009-9236

VL - 95

SP - 254

EP - 257

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 3

ER -

Pharmacogenomics in psychiatry: From therapeutic drug monitoring to genomic medicine

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto